Abstract: An HMI control device is configured to control an HMI device mounted in a vehicle, which is capable of performing an autonomous driving as a first task. The HMI control device is configured to: acquire a possible duration for the autonomous driving; and present, by the HMI device, a second task that an occupant on a driver's seat is able to start executing during the autonomous driving based on the possible duration acquired by the time acquisition unit.

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

Abstract: A drive mode switch control device acquires operation information. The drive mode switch control device switches a drive state among at least an autonomous drive state, a manual drive state, and a coordination drive state. The operation detection unit detects a first operation and a second operation based on the operation information when the drive state is not in the manual drive state. The second operation is the drive operation different from the first operation and input after the input of the first operation. The drive mode switch control device switches the drive state from the autonomous drive state to the coordination drive state based on a detection determination of the first operation. The drive mode switch control device switches the drive state from the coordination drive state to the manual drive state based on a detection determination of the first operation.

Abstract: An HMI control device, which controls an HMI device mounted on a vehicle. The HMI device presents information to a driver of the vehicle in a recognizable manner. The vehicle is capable of automated driving and travels following a preceding vehicle at a speed equal to or lower than a predetermined speed. The HMI control device is configured to: present attention information for calling attention of the driver when a congestion is determined to be cleared; acquire a behavior of the driver; and end a second task presented on the HMI device at an end timing corresponding to the behavior of the driver acquired after presentation of the attention information.

Abstract: An HMI device for presenting information recognizably by an occupant of a vehicle capable of autonomous driving is controlled. An acceleration and deceleration state, which is an execution status of acceleration and deceleration control in the vehicle during autonomous driving, is acquired. Acceleration and deceleration information relating to the acceleration and deceleration state is presented in a mode corresponding to the acceleration and deceleration state.

Abstract: A drive mode switch control device acquires operation information. The drive mode switch control device switches a drive state among at least an autonomous drive state, a manual drive state, and a coordination drive state. The operation detection unit detects a first operation and a second operation based on the operation information when the drive state is not in the manual drive state. The second operation is the drive operation different from the first operation and input after the input of the first operation. The drive mode switch control device switches the drive state from the autonomous drive state to the coordination drive state based on a detection determination of the first operation. The drive mode switch control device switches the drive state from the coordination drive state to the manual drive state based on a detection determination of the first operation.

Abstract: An HMI control device includes an automation level acquisition portion and a display control unit. The automation level acquisition portion acquires an autonomous driving level determined by a driving control device. The display control portion controls an image display operation of an HMI device according to the autonomous driving level acquired by the automation level acquisition portion. When terminating a high autonomous driving level as the autonomous driving level, the display control portion controls the HMI device to provide an action instruction display that instructs the driver to take a low-level associated state so as to handle a low autonomous driving level. The low autonomous driving level is the autonomous driving level under which an in-vehicle system including the driving control device is prohibited from performing at least one of a lateral motion control realized by performing steering and a longitudinal motion control realized by performing acceleration/deceleration.

Abstract: An HCU is to be used in a vehicle including an autonomous driving operation, and includes a function of a presentation control device that controls presentation of information to a driver of the vehicle. The presentation control device determines interruption of a second task other than driving permitted to the driver in an autonomous traveling period where the vehicle travels by the autonomous driving operation. Based on the interruption determination of the second task, the HCU changes a provision method of content provided in association with the second task in the autonomous traveling period.

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: A drive mode switch control device acquires operation information. The drive mode switch control device switches a drive state among at least an autonomous drive state, a manual drive state, and a coordination drive state. The operation detection unit detects a first operation and a second operation based on the operation information when the drive state is not in the manual drive state. The second operation is the drive operation different from the first operation and input after the input of the first operation. The drive mode switch control device switches the drive state from the autonomous drive state to the coordination drive state based on a detection determination of the first operation. The drive mode switch control device switches the drive state from the coordination drive state to the manual drive state based on a detection determination of the first operation.

Abstract: An HMI control device is provided to control an HMI device mounted in a vehicle capable of autonomous steering control. The HMI control device is configured to: acquire an execution status of the autonomous steering control; acquire congestion information; acquire an entry status of the vehicle into a congestion section included in the congestion information; present, on the HMI device, the congestion information and lane information related to a possibility of a lane change in a case where the autonomous steering control is being executed and the entry status indicates an entry into the congestion section; and present, as the lane information, lane change information in a case where (i) a traffic congestion occurs in the congestion section of a different lane and (ii) a congestion traveling after a lane change from an own lane to the different lane in which the traffic congestion is occurred is recommended.

Abstract: An HMI control device is configured to control an HMI device mounted in a vehicle, which is capable of performing an autonomous driving as a first task. The HMI control device is configured to: acquire a possible duration for the autonomous driving; and present, by the HMI device, a second task that an occupant on a driver's seat is able to start executing during the autonomous driving based on the possible duration acquired by the time acquisition unit.

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: A vehicle involves driving mode switching between an autonomous driving state, in which the vehicle is responsible for implementing driving tasks including vehicle steering, vehicle driving, vehicle braking, and periphery monitoring, and a manual driving state or a driving assistance state, in which a driver of the vehicle is responsible for implementing at least one of the driving tasks. A driving task implementation unit implements the driving tasks based on a vehicle behavior plan, which indicates a vehicle behavior scheduled in the autonomous driving state. A vehicle behavior plan generation unit generates a second task priority plan, which is the vehicle behavior plan until the driving mode is switched from the autonomous driving state to the manual driving state, such that a convenient finish time, at which a second task implemented by the driver in the autonomous driving state is conveniently finished, comes before the driving mode switching.

Abstract: An execution of a second task of a driver is assisted in cooperation with a user interface in an autonomous driving state in which a vehicle is an execution entity of a driving task. The second task is extracted, which is properly executable within task possible time estimated as time in which the second task is executable in a route to a destination of the vehicle. The second task extracted by the second task extracting unit is suggested through the user interface.

Abstract: An information presentation control device controlling information presentation to a driver in a vehicle equipped with autonomous driving function is provided. The information presentation control device is configured to: obtain a margin of the driver until an execution of driving change in which the driver takes over the at least partial driving task being performed by the autonomous driving; control a playback mode of a content presented by the information presentation device; stop the content, which is in a playback state, at a stop position in response to the execution of driving change; and set, according to the margin of the driver, a restart position of the content to which the content is rewound from the stop position to restart a playback of the content.

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.